Summit Therapeutics stock is trading -32.83% below its average target price of $32.5 after dropping -1.4% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $12.004937 to $49.326496 per share.
Summit Therapeutics has an elevated short interest of 27.6%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 6.87. The company's insiders own 84.34% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Summit Therapeutics's rate of institutional ownership is 13.5%, which indicates a decent level of confidence in the stock. Based on these factors, Market Inference considers Summit Therapeutics to be the target of mixed market sentiment.
Institutions Invested in Summit Therapeutics
Date Reported | Holder | Percentage | Shares | Value |
---|---|---|---|---|
2025-06-30 | Baker Bros. Advisors, LP | 5% | 33,722,974 | $736,172,519 |
2025-06-30 | FMR, LLC | 1% | 9,226,376 | $201,411,787 |
2025-06-30 | Vanguard Group Inc | 1% | 8,673,672 | $189,346,259 |
2025-06-30 | Blackrock Inc. | 1% | 6,846,667 | $149,462,740 |
2025-06-30 | State Street Corporation | 1% | 4,017,697 | $87,706,325 |
2025-06-30 | Price (T.Rowe) Associates Inc | 1% | 3,905,148 | $85,249,380 |
2025-06-30 | Geode Capital Management, LLC | 0% | 2,934,815 | $64,067,011 |
2025-06-30 | Pictet Asset Management Holding SA | 0% | 2,163,873 | $47,237,347 |
2025-06-30 | UBS Group AG | 0% | 2,093,958 | $45,711,102 |
2025-06-30 | NORGES BANK | 0% | 1,389,862 | $30,340,687 |